John Fucci

BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas.

BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas.

SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki.

BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas.

BIOS Capital Management LP (BIOS Partners) is a venture capital firm founded in 2014 by Stella Robertson, Aaron Fletcher and Leslie Kreis. The firm is headquartered in Fort Worth, Texas.

SIRPant Immunotherapeutics, Inc. is a clinical-stage immuno-oncology company based in Hummelstown, PA. The company specializes in developing next-generation macrophage-based immunotherapies for the treatment of hematological malignancies and solid tumors. The cell therapy technology employed by SIRPant is based on the reduction of SIRP? expression combined with activation of the patient's own macrophages. This population of SIRP?low activated macrophages is designed to attack the tumor following injection by activating the patient's immune system to produce broad-spectrum anti-tumor activity that utilizes patient T-cells and antibodies targeting cancer neoantigens. The company was founded by Richard F. Fitzgerald, and the CEO is Robert J. Towarnicki.